Literature DB >> 35675041

Ecdysoneless Overexpression Drives Mammary Tumorigenesis through Upregulation of C-MYC and Glucose Metabolism.

Bhopal C Mohapatra1, Sameer Mirza1, Aditya Bele1, Channabasavaiah B Gurumurthy1, Mohsin Raza1, Irfana Saleem2, Matthew D Storck3, Aniruddha Sarkar1, Sai Sundeep Kollala3, Surendra K Shukla3, Siddesh Southekal1, Kay-Uwe Wagner3, Fang Qiu4, Subodh M Lele5,6, Mansour A Alsaleem7,8, Emad A Rakha7, Chittibabu Guda6, Pankaj K Singh1,2,3,6, Robert D Cardiff9, Hamid Band1,2,3,5,6, Vimla Band1,2,6.   

Abstract

Ecdysoneless (ECD) protein is essential for embryogenesis, cell-cycle progression, and cellular stress mitigation with an emerging role in mRNA biogenesis. We have previously shown that ECD protein as well as its mRNA are overexpressed in breast cancer and ECD overexpression predicts shorter survival in patients with breast cancer. However, the genetic evidence for an oncogenic role of ECD has not been established. Here, we generated transgenic mice with mammary epithelium-targeted overexpression of an inducible human ECD transgene (ECDTg). Significantly, ECDTg mice develop mammary hyperplasia, preneoplastic lesions, and heterogeneous tumors with occasional lung metastasis. ECDTg tumors exhibit epithelial to mesenchymal transition and cancer stem cell characteristics. Organoid cultures of ECDTg tumors showed ECD dependency for in vitro oncogenic phenotype and in vivo growth when implanted in mice. RNA sequencing (RNA-seq) analysis of ECDTg tumors showed a c-MYC signature, and alterations in ECD levels regulated c-MYC mRNA and protein levels as well as glucose metabolism. ECD knockdown-induced decrease in glucose uptake was rescued by overexpression of mouse ECD as well as c-MYC. Publicly available expression data analyses showed a significant correlation of ECD and c-MYC overexpression in breast cancer, and ECD and c-MYC coexpression exhibits worse survival in patients with breast cancer. Taken together, we establish a novel role of overexpressed ECD as an oncogenesis driver in the mouse mammary gland through upregulation of c-MYC-mediated glucose metabolism. IMPLICATIONS: We demonstrate ECD overexpression in the mammary gland of mice led to the development of a tumor progression model through upregulation of c-MYC signaling and glucose metabolism. ©2022 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35675041      PMCID: PMC9437571          DOI: 10.1158/1541-7786.MCR-22-0122

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  53 in total

Review 1.  The Multiple Functions of the PAQosome: An R2TP- and URI1 Prefoldin-Based Chaperone Complex.

Authors:  Jeffrey Lynham; Walid A Houry
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

2.  TXNIP interacts with hEcd to increase p53 stability and activity.

Authors:  Hyun-Woo Suh; Sohyun Yun; Haeyoung Song; Haiyoung Jung; Young-Jun Park; Tae-Don Kim; Suk Ran Yoon; Inpyo Choi
Journal:  Biochem Biophys Res Commun       Date:  2013-07-21       Impact factor: 3.575

3.  Ecdysoneless Protein Regulates Viral and Cellular mRNA Splicing to Promote Cervical Oncogenesis.

Authors:  Sameer Mirza; Achyuth Kalluchi; Mohsin Raza; Irfana Saleem; Bhopal Mohapatra; Dhananjaya Pal; Michel M Ouellette; Fang Qiu; Lulu Yu; Alexei Lobanov; Zhi-Ming Zheng; Ying Zhang; Mansour A Alsaleem; Emad A Rakha; Hamid Band; M Jordan Rowley; Vimla Band
Journal:  Mol Cancer Res       Date:  2021-10-20       Impact factor: 6.333

4.  Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.

Authors:  Marisa G Ponzo; Robert Lesurf; Stephanie Petkiewicz; Frances P O'Malley; Dushanthi Pinnaduwage; Irene L Andrulis; Shelley B Bull; Naila Chughtai; Dongmei Zuo; Margarita Souleimanova; David Germain; Atilla Omeroglu; Robert D Cardiff; Michael Hallett; Morag Park
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-17       Impact factor: 11.205

5.  EMT tumorigenesis in the mouse mammary gland.

Authors:  Patrizia Damonte; Jeffrey P Gregg; Alexander D Borowsky; Blaine A Keister; Robert D Cardiff
Journal:  Lab Invest       Date:  2007-10-08       Impact factor: 5.662

6.  Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.

Authors:  M L Prasad; Y Huang; N S Pellegata; A de la Chapelle; R T Kloos
Journal:  Histopathology       Date:  2004-07       Impact factor: 5.087

7.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.

Authors:  Elgene Lim; François Vaillant; Di Wu; Natasha C Forrest; Bhupinder Pal; Adam H Hart; Marie-Liesse Asselin-Labat; David E Gyorki; Teresa Ward; Audrey Partanen; Frank Feleppa; Lily I Huschtscha; Heather J Thorne; Stephen B Fox; Max Yan; Juliet D French; Melissa A Brown; Gordon K Smyth; Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Med       Date:  2009-08-02       Impact factor: 53.440

8.  Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.

Authors:  Xiangshan Zhao; Sameer Mirza; Alaa Alshareeda; Ying Zhang; Channabasavaiah Basavaraju Gurumurthy; Aditya Bele; Jun Hyun Kim; Shakur Mohibi; Monica Goswami; Subodh M Lele; William West; Fang Qiu; Ian O Ellis; Emad A Rakha; Andrew R Green; Hamid Band; Vimla Band
Journal:  Breast Cancer Res Treat       Date:  2012-01-22       Impact factor: 4.872

9.  Cytoplasmic expression of pontin in renal cell carcinoma correlates with tumor invasion, metastasis and patients' survival.

Authors:  Xiang Zhang; Juchao Ren; Lei Yan; Yueqing Tang; Wenhua Zhang; Dawei Li; Yuanwei Zang; Feng Kong; Zhonghua Xu
Journal:  PLoS One       Date:  2015-03-09       Impact factor: 3.240

10.  Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers.

Authors:  Daniel P Hollern; Matthew R Swiatnicki; Eran R Andrechek
Journal:  PLoS Genet       Date:  2018-01-18       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.